FIGURE 6.

In vivo gene silencing and antitumour activity of siCDK1@LEVs. (a) CDK1 mRNA and protein expression in tumours treated with different formulations for 21 days (n = 3; mean ± SD). (b) Tumour growth curves of tumour‐bearing mice treated with different formulations (n = 6; mean ± SD). ****p < 0.001 compared to free siCDK1. (c) Survival rate of tumour‐bearing mice in various groups. (d) Bodyweight of treated tumour‐bearing mice over time (n = 6; mean ± SD). (e) Representative H&E staining images of tumours and livers collected from mice after 21 days of treatment. Scale bar = 100 μm. (f) AST and ALT levels in mice blood at day 21 of treatment (n = 5; mean ± SD). (g) Histological assessment of the heart, spleen, lung and kidney via H&E staining. Scale bar = 100 μm. (h) TNF‐α and IL‐6 levels in ICR mice blood after 24 h of systematic administration tested using ELISA kits (n = 3; mean ± SD). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001